CA
BPMC

Clearstead Advisors’s Blueprint Medicines BPMC Stock Holding History

Clearstead Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-121
Closed -$15.5K – 3114
2025
Q2 		$15.5K Buy
121
+83
+218% +$8.62K ﹤0.01% 1728
2025
Q1 		$3.36K Sell
38
-25
-40% -$2.44K ﹤0.01% 1807
2024
Q4 		$5.5K Hold
63
– – ﹤0.01% 1702
2024
Q3 		$5.83K Sell
63
-35
-36% -$3.48K ﹤0.01% 1693
2024
Q2 		$10.6K Buy
+98
New +$9.81K ﹤0.01% 1541

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Clearstead Advisors's BPMC Position: Q3 2025 in Review

Clearstead Advisors sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 121 shares — an estimated $15.5K sold.

Clearstead Advisors first reported a position in BPMC in Q2 2024 and held it in 5 quarters. The position peaked at $15.5K in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • Clearstead Advisors reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • Clearstead Advisors sold 121 Blueprint Medicines shares in Q3 2025, an estimated $15.5K.
  • Clearstead Advisors first reported a position in Blueprint Medicines in Q2 2024 and held it in 5 quarters.
  • Clearstead Advisors's Blueprint Medicines position peaked at $15.5K in Q2 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Clearstead Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.